clinical trial · NCT06900192
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
Primary Progressive Multiple SclerosisMultiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary ProgressiveOrca-Qmyeloablative regimen
brief summary
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
started
Mar 1, 2025
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Mar 28, 2025
detailed description
This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of primary progressive MS.
official title
A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol